Background: Gene therapy is one treatment that may ultimately cure type 1 diabe-
| INTRODUCTION
Type I diabetes is caused by the autoimmune destruction of pancreatic β-cells. 1 Current treatment requires multiple daily injections of insulin to control blood glucose levels. Gene therapy is one strategy that holds promise with respect to a cure for the disease. Of the accessible primary cells available, our laboratory and others have shown that hepatocytes are suitable target cells for the genetic engineering of artificial β-cells. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Most importantly, liver cells express the high-capacity glucose transporter GLUT 2 14 and the high-capacity phosphorylation enzyme glucokinase, 15 which constitute the key elements of the 'glucose sensing system' that regulates insulin release from pancreatic β-cells in response to small extracellular nutrient changes. Studies have also shown that these insulin-secreting liver cells are resistant to the detrimental effects of classical β-cell cytotoxins and pro-inflammatory cytokines that play principal roles in the autoimmune process of diabetes. 10, [16] [17] [18] Additionally, no infiltrates of immune cells were found in nonobese diabetic (NOD) mice engineered to express insulin in their livers. 10, 17 Thus, liver cells are attractive candidates for the creation of artificial β-cells to cure diabetes.
To obtain high transduction rates in diabetic animal livers using a lentiviral vector, we developed a microsurgical procedure of intervallic infusion in full flow occlusion (FFO), which involves clamping the major veins and arteries to stop blood flow to the liver during injection of the vector into the portal circulation. This allowed the vector containing the insulin gene to remain isolated within the liver, with resultant high transduction rates: 60% in streptozotocin (STZ)-diabetic rats 9 and 42% in spontaneously-diabetic NOD mice. 10 Using this technique, similar results were seen in a pancreatectomised pig model.
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Diabetes was reversed in these animal models, with accompanying normal glucose tolerance and partial endocrine pancreatic transdifferentiation of the liver resulting from the expression of several β-cell transcription factors. Indeed, it is the normal glucose tolerance displayed by these animals that sets our studies using the FFO technique apart from other regimes that have expressed insulin alone in the liver with no pancreatic transdifferentiation. 10, 13 Attempts to induce pancreatic transdifferentiation using the delivery of pancreatic transcription factors (notably Pdx1) have resulted in concomitant exocrine transdifferentiaiton and significant tissue damage. 5, 7 To apply this form of gene therapy to the clinical situation, we must be able to show that primary human hepatocytes can undergo transduction with the insulin gene and also that these hepatocytes can undergo pancreatic transdifferentiation, as seen in livers of the animal models studied to date. [9] [10] [11] In the present study, we have utilised the FRG mouse model in which chimeric mouse-human livers can be readily established. 19, 20 FRG mice have tyrosinaemia type I (Fah −/− ) and lack both humoral and cell-mediated immunity as a consequence of Rag2 and Il2rg 21 via a lentiviral vector (HMD) 22 to the livers of STZ-diabetic FRG mice. This has resulted in reversal of diabetes, restoration of glucose tolerance, and partial endocrine pancreatic transdifferentiation of both mouse and human hepatocytes in vivo.
| MATERIALS AND METHODS

| Vector production
The HIV/MSCV (HMD)/INS-FUR lentiviral vector, which expresses both INS-FUR and enhanced green fluorescent protein (EGFP), was constructed as described previously. 9 The HMD lentiviral vector 22 has a HIV/murine stem cell virus hybrid long terminal repeat as the promoter and an internal ribosomal entry site, allowing bicistronic gene expression of both EGFP and INS-FUR. The vectors were produced by Ca 3 (PO 4 ) 2 precipitation in 293 T cells using conditioned medium, as described previously. 9 Culture medium was harvested 48 h after transfection and subjected to tangential flow filtration, 9 followed by pelleting of the vector (75 000 g for 2 h). 
| Immunofluorescence microscopic analysis
| Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses
For RT-PCR analysis, liver, pancreas and spleen were harvested at 60 days after vector infusion and snap-frozen in liquid nitrogen.
Control pancreas was also obtained from nondiabetic FRG mice.
Expression levels of transgenic insulin were examined in all tissues.
Total RNA was extracted using Trizol (Invitrogen/ThermoFisher Table S1 ).
Melt curve analysis was performed to determine primer specificity.
Pre-optimised TaqMan Gene expression Assays (Applied Biosystems/ ThermoFisher Scientific, Waltham, MA, USA) were also used for the quantitation of the expression of mouse Pdx1, NeuroD1, Pax4, Ngn3, Nkx6.1 and MafA. TaqMan gene expression assays identification numbers are available in the Supporting information (Table S2) . TaqMan assays for the reference gene, mouse β-actin, were also obtained and used for the quantitation of expression levels of the genes of interest.
Taqman RT-qPCR assays were performed using the TaqMan Fast Advance Master Mix (Applied Biosystems/ThermoFisher Scientific), in accordance with the manufacturer's instructions. The reactions were performed using the QuantStudio 6 Flex Real Time PCR System (ThermoFisher Scientific). Data were represented using the 2 -ΔΔt method where
Reference ) sample tissue . The fold change in the target gene expression levels, normalised to β-actin and measured relative to the expression levels in the control tissue, was calculated for each sample. The mean ± SEM fold change in the expression levels for each gene was then determined. The QuantStudio 6 & 7 Flex Real-Time PCR System software was used to obtain the melting curves, the C t values for the target and reference genes, the ΔC t , the ΔΔC t values, as well as fold change differences in target gene expression levels in the different samples. Reactions were carried out in triplicate and experiments for each target gene were performed at least five times.
| Statistical analysis
Differences between groups were determined by a repeated measures analysis of variance. Log transformation of data was used where variances were heterogeneous. All other data was analysed using twotailed Student's t-tests. Data are expressed as the mean ± SEM.
p < 0.05 was considered statistically significant. 92.9 ± 10% of cells, with 88.6 ± 9.8% of cells staining positive for both human FAH and albumin. As expected, staining for human FAH and albumin in non-engrafted mice was negative ( Figure 1B) . Figure 1C represents a no antibody and no DAPI control of the mouse in Figure 1A , where no staining is visible.
| Reversal of diabetes in FRG mice
Blood glucose levels of diabetic FRG mice decreased to normal levels Figure 4D ), indicating that β-cell regeneration had not occurred.
Staining for insulin together with PDX1 once again showed marked staining for insulin (37.5 ± 4.1%) and PDX1 (33.5 ± 3.5%), with no significant difference between them ( Figure 4E ). By comparison, insulin and PDX1 were not detected in normal engrafted FRG livers ( Figure 4F ).
| Detection and quantification of expression levels of β-cell transcription factors and pancreatic hormones in FRG mouse livers transduced with INS-FUR
As expected from previous studies employing the FFO technique for the delivery of INS-FUR to animal livers, 9-11 INS-FUR expression was exclusively restricted to the livers of the FRG mice ( Figure 5A ). Table S3 ). The results showed upregulation of several β-cell transcription factors ( Figure 5C ) and pancreatic hormones ( Figure 5D ). Marked upregulation of human The engraftment success rate of human hepatocytes was high (50-62%) without the requirement for serial transplantation of hepatocytes, as described in other studies. 20 This was likely related to the fact that engrafted hepatocytes were allowed to expand for 150 days prior to diabetes induction and experimentation. As seen in other studies, 19, 20 serial sectioning and immunohistochemical analysis showed that, in areas of liver heavily repopulated with human hepatocytes, a high proportion of the cells (89%) showed dual positivity for human FAH and human albumin, confirming their human origin, because the murine hepatocytes in the FRG livers have an FAH deletion.
INS-FUR was not detected in livers of normal, FRG mice engrafted
As we previously described in studies using the FFO technique to to constitutive expression and unregulated secretion) 13 because the transduced hepatocytes had a reservoir of intracellular insulin, which allowed immediate responsiveness to increases in blood glucose concentrations, and insulin production was not reliant upon constitutive secretion 13 or the delayed response from a glucose-responsive promoter to stimulate transcription and not translation or secretion. 4 Insulin storage was approximately half that of a normal mouse pancreas, which is within clinical limits for islet transplantation. 25 The presence of the other pancreatic hormones glucagon and somatostatin in close proximity to the cells that stained positive for insulin may have assisted with the normal response to glucose; however, they were expressed at very low levels as assessed by immunohistochemical staining ( Figure 4A ), which would limit the possibility of a significant biological effect. Future in-depth determination of pancreatic transdifferentiation could be ascertained by RNA-seq analysis as described previously. 26 As a result of the coexistence of both human and murine hepatocytes in the humanised mice and the significant storage of human and mouse insulin in transduced livers, it is a reasonable assumption that both populations of hepatocytes underwent a degree of pancreatic transdifferentiation and contributed to the amelioration of diabetes.
We used RT-PCR and RT-qPCR to determine whether human hepato- creas. 27 MAFB was expressed in all murine samples, which corroborates our previous study using HMD/INS-FUR-transduced NOD mice, as well as other studies that have observed its expression at the mRNA level in liver tissue. 10, 28 32 Indeed, the exposure of liver cells to toxins and cellular insults has been shown to induce liver-to-pancreas transdifferentiation. 33 In the untransduced chimeric liver, the human hepatocytes were exposed to less damage than the mouse hepatocytes, which were FAH deficient and further damaged by urokinase treatment, prior to human liver cell engraftment.
The present study is the study to show clear transdifferentiation of human hepatocytes with storage of human insulin and the expression of human β-cell transcription factors and pancreatic hormones in an in vivo setting using a lentiviral system to deliver INS-FUR alone.
However, the results of the present study do not provide a definitive answer regarding which transduced liver cell type, mouse or human, made the greatest contribution to the reversal of diabetes and normal glucose tolerance observed in the FRG mouse.
It has been established in our previous study utilising NOD mice, 10 as well as in a study by Elsner et al. 13 using diabetic rats, that the simple injection of a lentiviral vector containing a modified insulin transgene was sufficient to reduce daily blood glucose levels to near normal. However, no storage of insulin in the livers was detected and glucose tolerance was abnormal. Because pancreas and liver come from the same endodermal origin, it has been reported previously that certain conditions such as insults to the cells or high glucose conditions can prime hepatocytes for pancreatic transdifferentiation. 33 It is therefore likely 
